Home » Posts tagged with » California
Cancer immunotherapy company EpicentRx raises $35m in Series D round

Cancer immunotherapy company EpicentRx raises $35m in Series D round

EpicentRx, a cancer immunotherapy company based in California, has secured $35 million of capital through a Series D financing round to support the development of small molecule immunotherapy and its oncolytic viral platform. The oncology company used the services of Biotech Alliances International, a Silicon Valley based life-science focused investment bank to get the funding. […]

Mirum gets FDA breakthrough therapy status for maralixibat for Alagille syndrome

Mirum Pharmaceuticals has secured the breakthrough therapy designation for maralixibat from the US Food and Drug Administration (FDA) for the treatment of pruritus associated with Alagille syndrome (ALGS) in patients, aged 1 year and older. The California-based biopharma company is engaged in the development and commercialization of new therapies for debilitating liver diseases. Alagille syndrome […]

Continue reading …
DAZZLE clinical trial : Kodiak Sciences doses first patients with KSI-301 in phase 3 wet AMD trial

Kodiak Sciences said that it has treated the first patients in the phase 2 DAZZLE clinical trial of KSI-301, its investigational intravitreal anti-VEGF antibody biopolymer conjugate, in wet age-related macular degeneration (wet AMD). The DAZZLE trial (also called KSI-CL-102) is designed to assess the safety and efficacy of KSI-301 in AMD patients who are treatment-naïve. […]

Continue reading …
Agilent acquires BioTek Instruments for $1.16bn

Agilent acquisition of BioTek : US-based lab instrument manufacturer Agilent Technologies has wrapped up its previously announced $1.16 billion acquisition of life science instrumentation manufacturer BioTek Instruments. The acquisition, which was announced in July 2019, is expected to boost Agilent’s position in the growing cell analysis segment. It was in 2015 when Agilent forayed into […]

Continue reading …
Graybug Vision initiates ALTISSIMO clinical trial for GB-102 in wet AMD

Graybug Vision has initiated the ALTISSIMO clinical trial, a phase 2b study, which will evaluate its pan-VEGF receptor inhibitor GB-102 in patients with wet age-related macular degeneration (wet AMD). Based in California, Graybug Vision is a clinical-stage pharma company engaged in developing drugs for ocular diseases like wet AMD, diabetic macular edema (DME), primary open […]

Continue reading …
Amphivena Therapeutics raises $62m to advance AMV564 into solid tumors

Amphivena Therapeutics funding round : Amphivena Therapeutics has raised $62 million in a Series C financing round to expand the clinical development of its lead candidate AMV564 into solid tumors and also to develop its T cell engagement portfolio. Based in California, Amphivena Therapeutics is a clinical-stage immuno-oncology company focused on developing T cell engager […]

Continue reading …
Annexon gets FDA fast track status for ANX005 in Guillain-Barré Syndrome

Annexon Biosciences has bagged the fast track designation for its C1q inhibitor ANX005 from the US Food and Drug Administration (FDA) for the treatment of Guillain-Barré Syndrome (GBS). Considered to be a rare, acute, antibody-mediated autoimmune disease, Guillain-Barré Syndrome affects the peripheral nervous system for which there are no approved therapies in the US till […]

Continue reading …
Cutera truSculpt iD body sculpting treatment gets expanded approval in Canada

Cutera said that Health Canada has expanded approval for its truSculpt iD body sculpting treatment to cover its use for the reduction of circumference of the abdomen and non-invasive lipolysis, which is the permanent removal of fat cells from the body. According to American Society for Aesthetic Plastic Surgery and Medical Insight (MII), noninvasive body sculpting […]

Continue reading …
Aytu BioScience to acquire Innovus Pharmaceuticals

Aytu acquisition of Innovus : Colorado-based specialty pharma company Aytu BioScience has agreed to acquire Innovus Pharmaceuticals in a deal worth up to $24 million, as per the latest pharma acquisition news. Headquartered in California, Innovus Pharmaceuticals is an over the counter (OTC) consumer goods and specialty pharmaceutical company. On the other hand, Aytu BioScience […]

Continue reading …
BioMed, University of California open cancer research center in San Diego

The University of California San Diego (UC San Diego) and BioMed Realty have opened the Center for Novel Therapeutics (CNT) – a new cancer research center at the former’s Science Research Park in San Diego, California. The cancer research center in San Diego, which spans 137,500sft, has been developed with an investment of $92 million […]

Continue reading …
Page 1 of 3123